These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 12490615)

  • 1. Constitutive coupling of a chimeric dopamine D2/alpha 1B receptor to the phospholipase C pathway: inverse agonism to silent antagonism by neuroleptic drugs.
    Wurch T; Boutet-Robinet EA; Palmier C; Colpaert FC; Pauwels PJ
    J Pharmacol Exp Ther; 2003 Jan; 304(1):380-90. PubMed ID: 12490615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
    Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
    Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
    Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic dopamine-antagonist interactions at recombinant human dopamine D(2short) receptor: dopamine-bound versus antagonist-bound receptor states.
    Pauwels PJ; Finana F; Tardif S; Wurch T; Colpaert FC
    J Pharmacol Exp Ther; 2001 Apr; 297(1):133-40. PubMed ID: 11259537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-time analysis of dopamine: antagonist interactions at recombinant human D2long receptor upon modulation of its activation state.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    Br J Pharmacol; 2001 Sep; 134(1):88-97. PubMed ID: 11522600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
    Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism.
    Pauwels PJ; Tardif S; Wurch T; Colpaert FC
    J Pharmacol Exp Ther; 2000 Feb; 292(2):654-63. PubMed ID: 10640303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
    Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of the mechanism of agonist and inverse agonist action at D2 dopamine receptors.
    Roberts DJ; Lin H; Strange PG
    Biochem Pharmacol; 2004 May; 67(9):1657-65. PubMed ID: 15081865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
    Millan MJ; Mannoury la Cour C; Novi F; Maggio R; Audinot V; Newman-Tancredi A; Cussac D; Pasteau V; Boutin JA; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2008 Feb; 324(2):587-99. PubMed ID: 18024789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
    Pauwels PJ; Gouble A; Wurch T
    Biochem J; 1999 Oct; 343 Pt 2(Pt 2):435-42. PubMed ID: 10510311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D2 receptor-mediated G protein activation assessed by agonist-stimulated [35S]guanosine 5'-O-(gamma-thiotriphosphate) binding in rat striatal membranes.
    Odagaki Y; Toyoshima R
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1304-12. PubMed ID: 16824659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
    Newman-Tancredi A; Cussac D; Audinot V; Nicolas JP; De Ceuninck F; Boutin JA; Millan MJ
    J Pharmacol Exp Ther; 2002 Nov; 303(2):805-14. PubMed ID: 12388667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.
    Hall DA; Strange PG
    Br J Pharmacol; 1997 Jun; 121(4):731-6. PubMed ID: 9208141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential signalling of both wild-type and Thr(343)Arg dopamine D(2short) receptor by partial agonists in a G-protein-dependent manner.
    Pauwels PJ; Tardif S; Colpaert FC
    Biochem Pharmacol; 2001 Sep; 62(6):723-32. PubMed ID: 11551517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.
    Malmberg ; Mikaels ; Mohell N
    J Pharmacol Exp Ther; 1998 Apr; 285(1):119-26. PubMed ID: 9536001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.